DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are ...

A European consensus statement says antithrombotic treatment for acute coronary syndromes should adjust for sex differences ...

If completed, the deal would mark the largest-ever acquisition by an Indian pharmaceutical company, surpassing Biocon ...

Aurobindo Pharma shares fell nearly 5% to ₹1,039 amid reports it may acquire Zentiva for $5-5.5 billion. This would be the ...

Aurobindo Pharma shares fell 4.67 per cent to hit a high of Rs 1,039.30 on BSE, commanding a market capitalisation of just ...

Reports suggested it has emerged as the frontrunner to acquire Prague-based Zentiva for $5 to $5.5 billion. If completed, this would be the largest-ever acquisition by an Indian pharma company.